Pharmaceutical company touts 'breakthrough' cancer treatment


Patients participating in a trial for a new lung cancer treatment have shown signs of improved health, leading the pharmaceutical company behind the study to hail a major "breakthrough” in the field.

>> Read more trending news

The American company Bristol-Myers Squibb reported Monday that lung cancer patients treated with a combination of its anti-tumor drug Opdivo and its melanoma drug Yervoy showed encouraging results.

According to the company, the treatment fared better than chemotherapy for individuals with "first-line advanced non-small cell lung cancer," known as NSCLC.

>> Related: Just one drink a day can increase your risk of cancer, study warns

"This Phase 3 study shows superior PFS (progression-free survival) with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB (tumor mutation burden)," Dr. Matthew D. Hellmann, study investigator and medical oncologist at Memorial Sloan Kettering Cancer Center, said in a press release.

Dr. Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb, said that his company sees the results as "a breakthrough in cancer research and a meaningful step forward in determining which first-line lung cancer patients may benefit most from the combination of Opdivo and Yervoy."

>> On AJC.com: 7 surprising things that can increase your risk of cancer

"These findings attest to our deep understanding of cancer biology, leading translational medicine capabilities and commitment to developing new approaches for cancer patients," he added.

The treatment trials are currently in their final phase, meaning the next step is to seek approval from the Food and Drug Administration to market the drug combination as a treatment for this specific condition. A panel of experts formed to assess the data recommended that the clinical trial move forward, despite some modifications made during the trial, according to the company.

>> Related: New cancer 'vaccine' completely wipes out tumors in mice -- human trials are on way

Bristol-Myers Squibb has been a pioneer in immunotherapy, according to Reuters. But some analysts are still holding out to see whether or not the treatment will be a success.

"Overall survival is what matters," BMO Capital Markets analyst Alex Arfaei said, explaining that regulators prefer that standard.

"The survival benefit may not be that great," he added, pointing to other new promising treatments.

One analyst called the study "a clear win" for the company, but another cautioned that the report is "positive but unquantified data," according to Bloomberg.

Critics questioned whether the pharmaceutical company’s clinical trial design change may have sullied the results.

>> Related: Long-term aspirin users at lower risk of cancer, study concludes

According to MarketWatch, researchers made changes to the Phase 3 trial, called CheckMate-227, while it was already ongoing.

Bristol-Myers management addressed the concerns Monday in a conference call, stating that it responded to emerging science and only made changes after conversations with the Food and Drug Administration.

Nonetheless, the company is hailing the trials as "a true example" of "innovation."

>> On AJC.com: ‘One-stop’ blood test to detect cancer shows promise, scientists say

Overall survival data from the Opdivo and Yervoy combination trial will be released near the end of 2018 or early in 2019 the company said.

Already, Opdivo is the company's best-selling drug, reporting sales of $4.95 billion globally last year.

"By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers," Bristol-Myers Squibb explained.

>> Related: 72 major genetic risk factors for breast cancer identified in new study

The new trials will likely increase the drug's profitability as they further demonstrate its benefits, the company said. However, Seamus Fernandez, an analyst at Leerink Partners, pointed out that it remains to be seen whether combining Opdivo with Yervoy provides better results than taking the drug alone.

For now, Bristol-Myers Squibb is thanking the patients who participated in the trial leading to the "breakthrough."

"We would like to thank the patients and researchers who participated in these clinical trials — without whom this scientific advance would not be realized," the company said in a statement.


Reader Comments ...


Next Up in Nation & World

Unsafe amounts of weed killer chemical found in some oat-based food, report finds
Unsafe amounts of weed killer chemical found in some oat-based food, report finds

Oatmeal and some other popular oat-based breakfast foods, including granola bars, may contain unsafe amounts of weed killer, according to a report.  The Environmental Working Group (EWG), an environmental organization that specializes in research and advocacy, conducted a study on 29 oat-based foods.  It found that all but five contained...
Former CIA Director John Brennan: ‘I will not relent’
Former CIA Director John Brennan: ‘I will not relent’

Shortly after White House press secretary Sarah Huckabee Sanders announced that President Donald Trump is revoking John Brennan’s security clearance, the former CIA director replied on Twitter:  Brennan later appeared in an MSNBC interview discussing the announcement. "I think Mr. Trump is getting more and more concerned...
Person bitten by shark off Cape Cod
Person bitten by shark off Cape Cod

A person was bitten by a shark off Cape Cod, sources tell Boston 25 News. >> Read more trending news  The harbormaster said that a Medflight has been called to take the victim to Tufts Medical Center. Crews are now out looking for the shark. The victim reportedly has "deep puncture wounds." Truro police are handling the investigation...
1 dead in fatal industrial accident near Walt Disney World employee area
1 dead in fatal industrial accident near Walt Disney World employee area

A 61-year-old man has died after an industrial accident near a Walt Disney World employee area, the Orange County Sheriff’s Office said. >> Read more trending news  According to deputies, two employees were emptying oil and grease byproduct from a semitrailer into a vat at the Harvest Power energy facility in Reedy Creek near...
‘John Doe’ buried in Georgia ID’ed by DNA as Michigan teen missing 39 years
‘John Doe’ buried in Georgia ID’ed by DNA as Michigan teen missing 39 years

Forensic experts on Tuesday identified a body buried in Georgia for nearly 40 years as a 15-year-old Michigan boy who was reported missing in 1979. Andrew Jackson Greer Jr., of Clayton, vanished Feb. 12, 1979, after leaving Addison High School and failing to return home. Michigan State Police officials said in a news release that the cold case...
More Stories